Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 13/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2057846 | 0.92 | EGLN1 (0.43) | EGLN1TBXAS1PTAFRHIF1A | |
| SCHEMBL2057284 | 0.80 | KDM4E (0.47) | EGLN1 | |
| SCHEMBL2058021 | 0.76 | EGLN1 (0.39) | EGLN1HIF1A | |
| SCHEMBL2057951 | 0.75 | NPC1 (0.43) | EGLN1 | |
| SCHEMBL834904 | 0.68 | ATM (0.72) | EGLN1HIF1AATM | |
| SCHEMBL15846617 | 0.67 | KMT2A (0.48) | EGLN1HIF1A | |
| SCHEMBL2761676 | 0.67 | HIF1A (0.46) | EGLN1HIF1A | |
| SCHEMBL336966 | 0.67 | HIF1A (0.50) | EGLN1HIF1A | |
| SCHEMBL522268 | 0.66 | THRA (0.72) | EGLN1 | |
| SCHEMBL2181308 | 0.66 | EGLN1 (0.72) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | claimed |
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| WO-2010022307-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885TBXAS1 619/4885PTAFR 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.